Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Impact Biomedicines Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and the same number of distinct art units. This variety suggests that the company's current applications are being reviewed by different technical specialists. This distribution requires the company to manage two separate prosecution tracks simultaneously.
Saeed, Ali S is the busiest examiner for the portfolio, with 1 pending office action. With 2 pending actions and two distinct examiners, each examiner is responsible for exactly one action. This distribution means that the company must navigate two different examiner styles and art unit standards concurrently. Practitioners should monitor the distinct approaches of these examiners to identify any variations in prosecution style across the different technical groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, ALI S | 1 | 31.3% | +35.8% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18591064 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | SAEED, ALI S | 56d overdue |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18591064 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS | SAEED, ALI S | 1616 | §103DP | Non-Final OA | 56d overdue | Pending | Feb 29, 2024 |
| 18257770 | DOSING OF FEDRATINIB | YOO, SUN JAE | 1621 | §102 | Non-Final OA | — | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial